HEREDITARY ANGIOEDEMA (HAE)
Clinical trials for HEREDITARY ANGIOEDEMA (HAE) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA (HAE) trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA (HAE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for HAE sufferers: Long-Term drug trial launches
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of a drug called navenibart for people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. It is for adults and teens who were in a previous navenibart study. Participants will receive navenib…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 10:26 UTC
-
UK study tracks HAE patients on lanadelumab: fewer attacks expected
Disease control OngoingThis study looks at 50 people in the UK with hereditary angioedema (HAE) who are starting or have started lanadelumab. Researchers will compare the number of swelling attacks in the year before starting the drug to up to two years after. Data comes from medical records, diaries, …
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 10:26 UTC
-
New daily pill could stop HAE attacks in their tracks
Disease control OngoingThis study tests a once-daily pill called deucrictibant to prevent painful swelling attacks in people aged 12 and older with hereditary angioedema (HAE). Participants receive either the drug or a placebo for 24 weeks to see if it reduces attack frequency. The goal is to provide a…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New study tracks TAKHZYRO's safety for swelling disorder over one year
Disease control OngoingThis study monitors 155 people in Japan with hereditary angioedema (HAE) who are taking TAKHZYRO (lanadelumab) for the first time. Researchers will track side effects and how well the drug controls swelling attacks over 12 months. The goal is to confirm the medicine's safety and …
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New pill could quickly stop swelling attacks in hereditary angioedema
Disease control ENROLLING_BY_INVITATIONThis study is testing an oral medication called deucrictibant for quickly treating swelling attacks in people with hereditary angioedema (HAE), including dangerous throat swelling. It involves 150 adults who have previously been in related studies or are new to the drug. The goal…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE2, PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New hope for HAE patients: experimental drug aims to slash attack rate
Disease control OngoingThis study tests an experimental drug called BW-20805 in 25 adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The goal is to see if the drug can reduce how often these attacks happen over 24 weeks. Participants will receive the dru…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE2 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 01, 2026 15:56 UTC